Déterminants sociaux de la santé : Questions médicales fréquentes
Nom anglais: Social Determinants of Health
Descriptor UI:D064890
Tree Number:N01.400.675
Termes MeSH sélectionnés :
Hyperthermic Intraperitoneal Chemotherapy
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Déterminants sociaux de la santé : Questions médicales les plus fréquentes",
"headline": "Déterminants sociaux de la santé : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Déterminants sociaux de la santé : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-20",
"dateModified": "2025-04-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Santé",
"url": "https://questionsmedicales.fr/mesh/D006262",
"about": {
"@type": "MedicalCondition",
"name": "Santé",
"code": {
"@type": "MedicalCode",
"code": "D006262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N01.400"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Déterminants sociaux de la santé",
"alternateName": "Social Determinants of Health",
"code": {
"@type": "MedicalCode",
"code": "D064890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mofya S Diallo",
"url": "https://questionsmedicales.fr/author/Mofya%20S%20Diallo",
"affiliation": {
"@type": "Organization",
"name": "Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Keck School of Medicine at the University of Southern California, 4650 Sunset Boulevard, MS#3, Los Angeles, CA 90027, USA. Electronic address: modiallo@chla.usc.edu."
}
},
{
"@type": "Person",
"name": "Sacharitha Bowers",
"url": "https://questionsmedicales.fr/author/Sacharitha%20Bowers",
"affiliation": {
"@type": "Organization",
"name": "Division of Dermatology, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, 1S260 Summit Ave, Oakbrook Terrace, IL 60181, USA. Electronic address: sachbow@gmail.com."
}
},
{
"@type": "Person",
"name": "Aileen Y Chang",
"url": "https://questionsmedicales.fr/author/Aileen%20Y%20Chang",
"affiliation": {
"@type": "Organization",
"name": "Department of Dermatology, University of California San Francisco, Zuckerberg San Francisco General Hospital, 995 Potrero Avenue, Building 90, Ward 92, San Francisco, CA 94110, USA."
}
},
{
"@type": "Person",
"name": "Christina Pardo",
"url": "https://questionsmedicales.fr/author/Christina%20Pardo",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA. Electronic address: chp4022@med.cornell.edu."
}
},
{
"@type": "Person",
"name": "Julianne Holt-Lunstad",
"url": "https://questionsmedicales.fr/author/Julianne%20Holt-Lunstad",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, Brigham Young University, Provo, Utah, USA; email: julianne_holt-lunstad@byu.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta-analysis.",
"datePublished": "2022-05-20",
"url": "https://questionsmedicales.fr/article/35485982",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/odi.14228"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of TTF-1 Expression on the Prognostic Prediction of Patients with NSCLC with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs Chemoimmunotherapy: A Multicenter, Retrospective Study.",
"datePublished": "2024-10-25",
"url": "https://questionsmedicales.fr/article/39482992",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4143/crt.2024.748"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial.",
"datePublished": "2024-10-03",
"url": "https://questionsmedicales.fr/article/39358654",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00262-024-03815-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lesson from COVID-19 outbreak; importance of standard precautions to febrile neutropenia prevention in patients with breast cancer who received adjuvant chemotherapy: a retrospective observational study.",
"datePublished": "2024-09-30",
"url": "https://questionsmedicales.fr/article/39416881",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4174/astr.2024.107.4.195"
}
},
{
"@type": "ScholarlyArticle",
"name": "HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy.",
"datePublished": "2024-09-07",
"url": "https://questionsmedicales.fr/article/39272960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/cancers16173102"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Caractéristiques de la population",
"item": "https://questionsmedicales.fr/mesh/D011154"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé",
"item": "https://questionsmedicales.fr/mesh/D006262"
},
{
"@type": "ListItem",
"position": 4,
"name": "Déterminants sociaux de la santé",
"item": "https://questionsmedicales.fr/mesh/D064890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Déterminants sociaux de la santé - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Déterminants sociaux de la santé",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Déterminants sociaux de la santé",
"description": "Comment évaluer l'impact des déterminants sociaux sur la santé ?\nQuels outils mesurent les déterminants sociaux de la santé ?\nQuels indicateurs sont utilisés pour le diagnostic social ?\nComment les inégalités sociales affectent-elles la santé ?\nQuel rôle joue l'environnement dans le diagnostic social ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Déterminants sociaux de la santé",
"description": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?\nComment la pauvreté affecte-t-elle la santé mentale ?\nQuels symptômes physiques sont liés à des conditions sociales ?\nLes inégalités sociales provoquent-elles des symptômes spécifiques ?\nComment l'accès limité aux soins se manifeste-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Déterminants sociaux de la santé",
"description": "Quelles stratégies de prévention ciblent les déterminants sociaux ?\nComment sensibiliser aux déterminants sociaux de la santé ?\nQuel rôle des communautés dans la prévention ?\nComment les politiques publiques influencent-elles la prévention ?\nQuels programmes de prévention sont efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Déterminants sociaux de la santé",
"description": "Comment adapter les traitements aux déterminants sociaux ?\nQuels traitements sont efficaces pour les populations défavorisées ?\nComment les services de santé peuvent-ils réduire les inégalités ?\nQuel rôle joue l'éducation dans le traitement des maladies ?\nComment les politiques de santé influencent-elles les traitements ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Déterminants sociaux de la santé",
"description": "Quelles complications sont liées aux inégalités sociales ?\nComment les déterminants sociaux aggravent-ils les maladies ?\nQuels sont les effets à long terme des déterminants sociaux ?\nComment prévenir les complications liées aux déterminants sociaux ?\nLes complications de santé sont-elles évitables ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Déterminants sociaux de la santé",
"description": "Quels sont les principaux facteurs de risque sociaux ?\nComment l'éducation influence-t-elle les facteurs de risque ?\nQuel impact a l'emploi sur la santé ?\nComment l'environnement social affecte-t-il la santé ?\nQuels facteurs de risque sont liés à l'accès aux soins ?",
"url": "https://questionsmedicales.fr/mesh/D064890?mesh_terms=Hyperthermic+Intraperitoneal+Chemotherapy&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'impact des déterminants sociaux sur la santé ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact peut être évalué par des études épidémiologiques et des enquêtes sociales."
}
},
{
"@type": "Question",
"name": "Quels outils mesurent les déterminants sociaux de la santé ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des indices de conditions de vie sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels indicateurs sont utilisés pour le diagnostic social ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indicateurs incluent le revenu, l'éducation, et l'accès aux soins de santé."
}
},
{
"@type": "Question",
"name": "Comment les inégalités sociales affectent-elles la santé ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inégalités sociales peuvent entraîner des disparités dans l'accès aux soins et la santé."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement dans le diagnostic social ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'environnement physique et social influence la santé par l'accès aux ressources."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer des déterminants sociaux défavorables ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes de stress, dépression ou maladies chroniques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Comment la pauvreté affecte-t-elle la santé mentale ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "La pauvreté peut entraîner une augmentation de l'anxiété et de la dépression."
}
},
{
"@type": "Question",
"name": "Quels symptômes physiques sont liés à des conditions sociales ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des maladies comme l'hypertension et le diabète peuvent être exacerbées par des conditions sociales."
}
},
{
"@type": "Question",
"name": "Les inégalités sociales provoquent-elles des symptômes spécifiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des symptômes de maladies évitables et chroniques."
}
},
{
"@type": "Question",
"name": "Comment l'accès limité aux soins se manifeste-t-il ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il se manifeste par des symptômes non traités et des complications de santé."
}
},
{
"@type": "Question",
"name": "Quelles stratégies de prévention ciblent les déterminants sociaux ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes d'éducation, d'accès aux soins et de soutien communautaire sont essentiels."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser aux déterminants sociaux de la santé ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Par des campagnes d'information et des formations pour les professionnels de santé."
}
},
{
"@type": "Question",
"name": "Quel rôle des communautés dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les communautés peuvent mobiliser des ressources et créer des réseaux de soutien."
}
},
{
"@type": "Question",
"name": "Comment les politiques publiques influencent-elles la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent promouvoir l'équité en santé et améliorer l'accès aux services."
}
},
{
"@type": "Question",
"name": "Quels programmes de prévention sont efficaces ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes intégrés qui abordent plusieurs déterminants sociaux sont les plus efficaces."
}
},
{
"@type": "Question",
"name": "Comment adapter les traitements aux déterminants sociaux ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements doivent tenir compte des ressources et des conditions de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels traitements sont efficaces pour les populations défavorisées ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les programmes de santé communautaire et les interventions ciblées sont efficaces."
}
},
{
"@type": "Question",
"name": "Comment les services de santé peuvent-ils réduire les inégalités ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "En offrant des soins accessibles et adaptés aux besoins des populations vulnérables."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'éducation dans le traitement des maladies ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éducation améliore l'adhésion aux traitements et la gestion des maladies."
}
},
{
"@type": "Question",
"name": "Comment les politiques de santé influencent-elles les traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles déterminent l'accès aux soins et les ressources disponibles pour les traitements."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées aux inégalités sociales ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies chroniques non traitées et des décès prématurés."
}
},
{
"@type": "Question",
"name": "Comment les déterminants sociaux aggravent-ils les maladies ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent entraîner un accès limité aux soins et une mauvaise gestion des maladies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme des déterminants sociaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent mener à des problèmes de santé persistants et à une qualité de vie réduite."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées aux déterminants sociaux ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "En améliorant l'accès aux soins et en renforçant les réseaux de soutien communautaire."
}
},
{
"@type": "Question",
"name": "Les complications de santé sont-elles évitables ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreuses complications peuvent être évitées par des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque sociaux ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent la pauvreté, le manque d'éducation et l'isolement social."
}
},
{
"@type": "Question",
"name": "Comment l'éducation influence-t-elle les facteurs de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une éducation supérieure est associée à une meilleure santé et à des comportements préventifs."
}
},
{
"@type": "Question",
"name": "Quel impact a l'emploi sur la santé ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un emploi stable améliore la santé mentale et physique, réduisant les risques."
}
},
{
"@type": "Question",
"name": "Comment l'environnement social affecte-t-il la santé ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement social positif favorise le bien-être et réduit les risques de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont liés à l'accès aux soins ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le manque d'accès aux soins médicaux et préventifs augmente les risques de maladies."
}
}
]
}
]
}
Head and neck squamous cell carcinoma (HNSCC) is among the common tumors associated with high mortality. The aim of our meta-analysis was to determine how additional anti-epidermal growth factor recep...
Thyroid transcription factor 1 (TTF-1) expression is a useful predictor of treatment efficacy in advanced non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate whether TTF-1 co...
We conducted a retrospective study of patients with NSCLC who were treated with chemotherapy or chemoimmunotherapy between March 2016 and May 2023. The patients had histologically confirmed NSCLC, sta...
This study included 283 of 624 patients. TTF-1-positive patients showed longer progression-free survival (PFS) and overall survival (OS) (PFS: 6.4 months [95% confidence interval (CI): 5.0-9.4] vs 4.1...
In patients with NSCLC with PD-L1 expression between 1% and 49%, TTF-1 expression was a predictor of chemotherapeutic, but not chemoimmunotherapeutic, efficacy....
The hemagglutinating virus of Japan envelope (HVJ-E) is an inactivated Sendai virus particle with antitumor effect and inducing antitumor immunity. However, its dosage and efficacy have not been verif...
Intensive cytotoxic chemotherapy increases the risk of infection in patients with cancer by inducing bone marrow suppression and mucosal injury. Febrile neutropenia (FN) is the most important clinical...
We retrospectively enrolled patients with breast cancer who received an adriamycin and cyclophosphamide (AC) regimen containing adjuvant chemotherapy at Jeju National University Hospital. We compared ...
In total, 149 patients were enrolled, including 94 who received AC chemotherapy in the pre-COVID-19 era and 55 who received it in the post-COVID-19 era. Sixteen patients (10.7%) experienced FN. Fourte...
We found an association between FN occurrence and the COVID-19 outbreak, providing indirect evidence of the importance of non-pharmacological measures to reduce FN risk in patients with breast cancer....
Maximal heterozygosity on the human leukocyte antigen (HLA) loci has been found to be associated with improved survival and development of immune-related adverse events (irAEs) among NSCLC patients tr...
We prospectively recruited patients with NSCLC who were commencing first-line pembrolizumab in combination with chemotherapy. DNA from white blood cells was used for high-resolution HLA-I/II typing....
Of the 65 patients recruited, 53 complied with the inclusion criteria. We did not find an association between HLA-I/-II homozygosity and clinical outcome among the studied population. However, the pre...
The absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a di...
To study the kinetics of blood count nadir and time to recovery and find its association with clinical outcomes in a cohort of Acute Lymphoblastic Leukemia (ALL)....
Data from 243 cases treated between January 2018 to December 2020 was retrospectively analysed. Along with baseline data, serial measures of peripheral blood counts, nadir, and time to partial and com...
Median age was 15 (range,1-62) years. Immunophenotype was B-ALL in 71% (n=172), and T-ALL in 27% (n=66). Good steroid response (D8) was seen in 89%(n=216), CR in 79% (n=192), and induction mortality i...
We found that a longer time to neutrophil nadir independently predicts refractory disease post-induction and late partial platelet recovery is an independent factor for poorer EFS and OS. Thus, Blood ...
In female Wistar rats, we studied the relationship between the levels of miR-21, miR-221, miR-222, and miR-429 in the lymph and morphometric parameters of the thymus after surgical treatment of breast...
Tinzaparin, a low-molecular weight heparin (LMWH), has shown anti-neoplastic properties in animal models and in in vitro studies of human cancer cell lines. The reduction of CA-125 levels during neoad...
This study aims to evaluate the potential anti-neoplastic effects of tinzaparin by investigating changes in serum CA-125 levels in advanced EOC patients who receive NACT....
This is an open randomized multicenter pilot trial. Forty patients with EOC selected to receive NACT will be randomized 1:1 to receive daily addition of tinzaparin or no tinzaparin. The processing and...
Inclusion criteria are women aged 18 years or older, World Health Organization performance status 0-1, histologically confirmed high-grade serous, endometrioid or clear cell EOC, International Federat...
This study will make an important contribution to the knowledge of the anti-neoplastic effects of tinzaparin in EOC patients and may thus guide the planning of a future study on the impact of tinzapar...
The primary aim of this study was to explore whether intravoxel incoherent motion (IVIM) can offer a contrast-agent-free alternative to dynamic contrast-enhanced (DCE)-MRI for measuring breast tumor p...
A total of 108 paired DWI and DCE-MRI scans were acquired at 1.5 T from 40 patients with primary breast cancer (median age: 44.5 years) before and during neoadjuvant chemotherapy (NACT). DWI parameter...
No statistically significant between-subject or within-subject correlation was found between the perfusion parameters estimated by IVIM and DCE-MRI (f versus v...
No correlations were observed between the perfusion parameters estimated by IVIM and DCE-MRI. This may be attributed to imprecise estimates of fxD...
NRF2 activation protects epithelial cells from malignancy, but cancer cells can upregulate the pathway to promote survival. NRF2 activators including CDDO-Methyl ester (CDDO-Me) inhibit cancer in prec...